<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>1889</id>
    <completedYear>2020</completedYear>
    <publishedYear/>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>1</pageFirst>
    <pageLast>17</pageLast>
    <pageNumber/>
    <edition/>
    <issue>Online/2020</issue>
    <volume>2020</volume>
    <type>article</type>
    <publisherName/>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2021-07-05</completedDate>
    <publishedDate>2020-12-17</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Survey about do-it-yourself closed loop systems in the treatment of diabetes in Germany</title>
    <abstract language="eng">Continuous glucose monitoring (CGM) improves treatment with lower blood glucose levels&#13;
and less patient effort. In combination with continuous insulin application, glycemic control&#13;
improves and hypoglycemic episodes should decrease. Direct feedback of CGM to continuous&#13;
subcutaneous insulin application, using an algorithm is called a closed-loop (CL)&#13;
artificial pancreas system. Commercial devices stop insulin application by predicting hypoglycemic&#13;
blood glucose levels through direct interaction between the sensor and pump. The&#13;
prediction is usually made for about 30 minutes and insulin delivery is restarted at the previous&#13;
level if a rise in blood glucose is predicted within the next 30 minutes (hybrid closed loop&#13;
system, HCL this is known as a predictive low glucose suspend system (PLGS)). In a fully&#13;
CL system, sensor and pump communicate permanently with each other. Hybrid closedloop&#13;
(HCL) systems, which require the user to estimate the meal size and provide a meal&#13;
insulin basis, are commercially available in Germany at the moment. These systems result&#13;
in fewer hyperglycemic and hypoglycemic episodes with improved glucose control. Open&#13;
source initiatives have provided support by building do-it-yourself CL (DIYCL) devices for&#13;
automated insulin application since 2014, and are used by a tech-savvy subgroup of&#13;
patients. The first commercial hybrid CL system has been available in Germany since September&#13;
2019. We surveyed 1054 patients to determine which devices are currently used,&#13;
which features would be in demand by potential users, and the benefits of DIYCL systems.&#13;
9.7% of these used a DIYCL system, while 50% would most likely trust these systems but&#13;
more than 85% of the patients would use a commercial closed loop system, if available. The&#13;
DIYCL users had a better glucose control regarding their time in range (TIR) and glycated&#13;
hemoglobin (HbA1c).</abstract>
    <parentTitle language="eng">Plos one</parentTitle>
    <identifier type="url">https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0243465</identifier>
    <identifier type="doi">https://doi.org/10.1371/journal. pone.0243465</identifier>
    <enrichment key="copyright">1</enrichment>
    <enrichment key="opus.source">publish</enrichment>
    <licence>Keine Lizenz - es gilt das deutsche Urheberrecht</licence>
    <author>Anna Laura Herzog</author>
    <editor>Maria Carmen Iglesias-Osma</editor>
    <author>Jonas Busch</author>
    <author>Christoph Wanner</author>
    <author>Holger K. von Jouanne-Diedrich</author>
    <subject>
      <language>deu</language>
      <type>swd</type>
      <value>Kontinuierliches Glucosemonitoring</value>
    </subject>
    <collection role="forschungsschwerpunkte" number="">Business Transformation and Innovation Management</collection>
    <file>https://opus4.kobv.de/opus4-h-ab/files/1889/journal.pone.0243465.pdf</file>
  </doc>
</export-example>
